DDR2 (T654M)

DDR2 · Variant type: point · HGVS: p.T654M

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	100.0%	0.0%	78.23
2	Cabozantinib	99.4%	0.6%	92.73
3	Entrectinib	99.2%	0.8%	93.69
4	Nintedanib	99.1%	0.9%	90.23
5	Repotrectinib	99.1%	0.9%	84.21
6	Pralsetinib	98.8%	1.2%	93.43
7	Gilteritinib	96.0%	4.0%	88.97
8	Ripretinib	95.3%	4.8%	92.95
9	Crizotinib	94.3%	5.7%	91.39
10	Tivozanib	93.6%	6.4%	92.42
11	Fedratinib	93.2%	6.8%	96.21
12	Pacritinib	89.2%	10.8%	88.64
13	Alpelisib	88.8%	11.2%	97.22
14	Fostamatinib	87.7%	12.3%	96.74
15	Brigatinib	87.2%	12.8%	82.96
16	Defactinib	86.4%	13.6%	92.68
17	Sunitinib	85.9%	14.1%	91.73
18	Sorafenib	85.5%	14.5%	96.72
19	Bosutinib	85.2%	14.8%	87.22
20	Tenalisib	79.6%	20.4%	97.98
21	Regorafenib	68.2%	31.8%	95.99
22	Quizartinib	66.4%	33.6%	99.50
23	Selpercatinib	63.3%	36.7%	96.72
24	Pazopanib	63.0%	37.0%	97.49
25	Upadacitinib	62.6%	37.4%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	100.0%	100.0%	-0.0%
Cabozantinib	99.4%	100.0%	-0.6%
Entrectinib	99.2%	—	—
Nintedanib	99.1%	100.0%	-0.9%
Repotrectinib	99.1%	98.3%	+0.9%
Pralsetinib	98.8%	95.9%	+3.0%
Gilteritinib	96.0%	96.7%	-0.6%
Ripretinib	95.3%	94.8%	+0.4%
Crizotinib	94.3%	—	—
Tivozanib	93.6%	99.3%	-5.7%
Fedratinib	93.2%	—	—
Pacritinib	89.2%	—	—
Alpelisib	88.8%	—	—
Fostamatinib	87.7%	—	—
Brigatinib	87.2%	—	—
Defactinib	86.4%	—	—
Sunitinib	85.9%	—	—
Sorafenib	85.5%	96.3%	-10.8%
Bosutinib	85.2%	97.6%	-12.4%
Tenalisib	79.6%	—	—
Regorafenib	68.2%	97.6%	-29.4%
Quizartinib	66.4%	—	—
Selpercatinib	63.3%	92.2%	-28.9%
Pazopanib	63.0%	—	—
Upadacitinib	62.6%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.6ms